Moderna, Inc.

MRNA

US60770K1079

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 02:30:00 07/02/2026 am IST			5-day change	1st Jan Change
41.01 ^USD	+0.34%		-6.94%	+39.06%

30/01	Leerink Partners Adjusts Moderna Price Target to $17 From $18, Maintains Underperform Rating	MT
30/01	Mib Outperforms Europe Ahead of S&P, Campari Leads Gains	AN

Moderna falls on doubts over new CDC panel's backing of RSV vaccine

Published on 06/13/2025 at 07:12 pm IST - Modified on 06/13/2025 at 09:14 pm IST

Reuters

Latest news about Moderna, Inc.

30/01	Leerink Partners Adjusts Moderna Price Target to $17 From $18, Maintains Underperform Rating	MT
30/01	Mib Outperforms Europe Ahead of S&P, Campari Leads Gains	AN
30/01	Moderna, Inc. Announces Executive and Committee Changes, Effective March 2, 2026	CI
30/01	Moderna CMO Jacqueline Miller to step down	RE
30/01	Markets Rise Amid Strong Euro and Earnings Season	AN
30/01	Recordati and Moderna Sign Global Agreement on mRNA Therapy for Rare Disease	AN
30/01	Moderna Collaborates With Recordati to Advance, Commercialize Investigational Therapy to Treat Metabolic Disorder	MT
30/01	Recordati announces collaboration with Moderna for mRNA-3927	RE
29/01	TD Cowen Adjusts Moderna Price Target to $40 From $25, Maintains Hold Rating	MT
29/01	Repertoire Immune Medicines, Eli Lilly Set Autoimmune Collaboration	DJ
29/01	Satellos Bioscience Inc. Appoints Antoinette Paone as Chief Development Officer and Head of Regulatory Affairs	CI
28/01	Wolfe Adjusts Price Target on Moderna to $25 From $17, Maintains Underperform Rating	MT
23/01	Bernstein Adjusts Price Target on Moderna to $35 From $25, Maintains Market Perform Rating	MT
23/01	The Market's Favorite Question Right Now: Is This a Return to Normal, or Just a Pause?
23/01	Analyst recommendations: Amgen, P&G, Spotify, Duolingo, Moderna…
23/01	Sector Update: Health Care Stocks Mixed Late Afternoon	MT
23/01	Sector Update: Health Care Stocks Rise in Afternoon Trading	MT
22/01	Moderna curbing investments in vaccine trials due to US backlash, CEO tells Bloomberg TV	RE
22/01	Moderna is curbing investment in vaccine trials due to US backlash - Bloomberg News	RE
22/01	Moderna Curbing Vaccine Trial Investments Over Backlash From US Officials	MT
22/01	Moderna Curbing Vaccine Trial Investments Over Backlash From US Officials, Bloomberg Reports	MT
22/01	Escalate, De-Escalate, Repeat
22/01	Stocks Gain Pre-Bell Amid Trump's Greenland Tariff Reversal; Investors Await Inflation Data	MT
22/01	Greenland Detente Levitates Wall Street Pre-Bell; Asia, Europe Rally	MT
22/01	Vaccine makers feel a chill as US Health Secretary Kennedy's rhetoric becomes reality	RE

Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows: - revenue from product sales (96.1%); - revenue from collaboration agreements (1.5%); - revenue from royalties and licensing (1.3%); - revenue from grants (1.1%). At the end of 2024, the group's portfolio comprises 37 products in clinical development, of which 10 in phase I, 18 in phase II and 9 in phase III, 3 products in preclinical development, and 4 products in commercial phase. Net sales are distributed geographically as follows: the United States (55.1%), Europe (18.5%) and other (26.4%).

Employees

5,800

Sector

Pharmaceuticals

Calendar

13/02 - Q4 2025 Earnings Release

More about the company